MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus
暂无分享,去创建一个
D. Jäger | C. E. Engeland | G. Ungerechts | S. Bossow | C. Grossardt | M. F. Leber | C. Kalle | M. Singh | M. Baertsch | J. Albert | M. Singh | Dirk Jäger | Christine E. Engeland | Christian Grossardt
[1] V. Lowe,et al. Remission of disseminated cancer after systemic oncolytic virotherapy. , 2014, Mayo Clinic proceedings.
[2] R. Cattaneo,et al. New viruses for cancer therapy: meeting clinical needs , 2013, Nature Reviews Microbiology.
[3] C. von Kalle,et al. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. , 2013, Human gene therapy.
[4] A. Enk,et al. Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus. , 2013, The Journal of investigative dermatology.
[5] A. Plückthun,et al. DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[6] S. Jäämaa,et al. MicroRNA-Mediated Suppression of Oncolytic Adenovirus Replication in Human Liver , 2013, PloS one.
[7] R. Cattaneo,et al. Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins , 2012, Cancer Gene Therapy.
[8] Xiaoliu Zhang,et al. Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] A. Carfi,et al. Targeted entry of enveloped viruses: measles and herpes simplex virus I. , 2012, Current opinion in virology.
[10] R. Cattaneo,et al. Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[11] Filip Pattyn,et al. The microRNA body map: dissecting microRNA function through integrative genomics , 2011, Nucleic acids research.
[12] E. Rieber,et al. Armed and targeted measles virus for chemovirotherapy of pancreatic cancer , 2011, Cancer Gene Therapy.
[13] C. von Kalle,et al. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[14] T. Fujiwara,et al. Enhanced Safety Profiles of the Telomerase-Specific Replication- Competent Adenovirus by Incorporation of Normal Cell-Specific microRNA-Targeted Sequences , 2011, Clinical Cancer Research.
[15] E. Izaurralde,et al. Gene silencing by microRNAs: contributions of translational repression and mRNA decay , 2011, Nature Reviews Genetics.
[16] K. Cichutek,et al. Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus. , 2010, Cancer research.
[17] R. Cattaneo,et al. Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics , 2010, Gene Therapy.
[18] L. Hartmann,et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. , 2010, Cancer research.
[19] S. Russell,et al. Attenuation of Vesicular Stomatitis Virus Encephalitis through MicroRNA Targeting , 2009, Journal of Virology.
[20] K. Ghoshal,et al. MicroRNA-122 Inhibits Tumorigenic Properties of Hepatocellular Carcinoma Cells and Sensitizes These Cells to Sorafenib* , 2009, The Journal of Biological Chemistry.
[21] P. Rennie,et al. MicroRNA Regulation of Oncolytic Herpes Simplex Virus-1 for Selective Killing of Prostate Cancer Cells , 2009, Clinical Cancer Research.
[22] S. Russell,et al. Engineering microRNA responsiveness to decrease virus pathogenicity , 2008, Nature Medicine.
[23] C. Croce,et al. MicroRNA involvement in hepatocellular carcinoma , 2008, Journal of cellular and molecular medicine.
[24] R. Andino,et al. Generation of a Conditionally Replicating Adenovirus Based on Targeted Destruction of E1A mRNA by a Cell Type-Specific MicroRNA , 2008, Journal of Virology.
[25] H. Atkins,et al. A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] D. Dingli,et al. Preclinical Pharmacology and Toxicology of Intravenous MV‐NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide , 2007, Clinical pharmacology and therapeutics.
[27] Yi-Hsuan Chen,et al. miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes , 2007, Nucleic Acids Res..
[28] R. Cattaneo,et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. , 2007, Cancer research.
[29] R. Cattaneo,et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[30] C. Sander,et al. A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing , 2007, Cell.
[31] T. Davison,et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma , 2007, Oncogene.
[32] C. Croce,et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. , 2007, JAMA.
[33] K. Ghoshal,et al. Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas , 2006, Journal of cellular biochemistry.
[34] C. Sander,et al. miR-122, a Mammalian Liver-Specific microRNA, is Processed from hcr mRNA and MayDownregulate the High Affinity Cationic Amino Acid Transporter CAT-1 , 2004, RNA biology.
[35] M. Billeter,et al. Rescue of measles viruses from cloned DNA. , 1995, The EMBO journal.
[36] J. Hardwick,et al. Apoptosis as a cause of death in measles virus-infected cells , 1995, Journal of virology.
[37] R Buckland,et al. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. , 1991, The Journal of general virology.
[38] U. Lauer,et al. Preclinical testing of virotherapeutics for primary and secondary tumors of the liver. , 2012, Methods in molecular biology.
[39] W. P. Duprex,et al. The measles virus replication cycle. , 2009, Current topics in microbiology and immunology.
[40] R. Ortíz-López,et al. Oncolytic virotherapy. , 2008, Annals of hepatology.
[41] R. Buckland,et al. Functional aspects of envelope-associated measles virus proteins. , 1995, Current topics in microbiology and immunology.